Werewolf Therapeutics

HOWL · NASDAQ

$1.05+$0.01 (+0.96%)TodayMarket closed · Oct 20, 7:51 PM ET

Prev close $1.04

HOWL analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $5.61 (+434.3% upside)

Low: $4.04
Now: $1.05
High: $7.35

Upgrades and downgrades

The latest rating actions, newest first

HOWL analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Dec 19, 2025	Maintains	Buy	$10.00 → $4.00	41%
B of A Securities	Nov 18, 2025	Maintains	Buy	$8.00 → $7.00	64%

The case for and against

Updated Feb 9, 2026

Bull case

Werewolf Therapeutics demonstrates a solid financial foundation through its innovative use of the proprietary PREDATOR platform, which positions the company to advance its unique INDUKINE therapies targeting the tumor microenvironment. The adjustment to Core FFO guidance, reflecting a midpoint increase of $0.03, indicates the company's ability to navigate costs effectively while still achieving growth. Additionally, the impressive metrics of 4.3% blended rent growth and 4.1% same-store NOI expansion showcase a thriving operational landscape, enhancing investor confidence in the company's future prospects.

Bear case

Werewolf Therapeutics Inc. faces a negative outlook due to lowered growth expectations reflected in its financial metrics. The company's performance indicators suggest a decline in revenue, alongside a 3.8% year-over-year rise in expenses, resulting in a 2.6% decline in net operating income (NOI). Additionally, average effective rental rates have decreased by 50 basis points year-over-year, attributed to a significant decline in new lease rates, indicating challenges in achieving desired growth against the backdrop of market supply conditions.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.